证券代码:603520 证券简称: 司太立 公告编号:2023-066 浙江司太立制药股份有限公司（以下简称"司太立"或"公司"）拟向特定 对象发行 A 股股票，募集资金不超过人民币 148,000 万元（含本数）； 本次向特定对象发行前后主要财务指标的分析、描述均不构成对公司的盈利 预测或承诺，制定填补回报措施不等于对公司未来利润做出保证，不构成任何投 资决策依据。如投资者据此进行投资决策而造成任何损失的，公司不承担任何责 任，提请广大投资者注意。 根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作 的意见》（国办发[2013]110 号）、中国证券监督管理委员会《关于首发及再融 资、重大资产重组摊薄即期回报有关事项的指导意见》（证监会公告[2015]31 号） 等有关文件的要求，公司对本次向特定对象发行摊薄即期回报对公司主要财务指 标的影响进行了认真分析，并提出了填补回报的具体措施，相关主体对公司填补 回报拟 采取的措施得到切实履行做出了承诺，具体内容说明如下： 浙江司太立制药股份有限公司 1 一、本次向特定对象发行摊薄即期回报对公司主要财务指标的影响 （一）财务指标计算主要假设和前提条件 ...

证券代码:603520 证券简称: 司太立 公告编号:2023-065 | 预案章节 | | 章节内容 | 修订情况 | | --- | --- | --- | --- | | 特别提示 | 特别提示 | | 更新了本次发行已履行的相关程序；更 | 1 | 预案章节 | 章节内容 | 修订情况 | | --- | --- | --- | | | | 新了本次发行拟募集资金总额，更新了 | | | | 各募投项目拟投入募集资金金额 | | | 三、本次发行方案 | | | | 五、本次发行是否导致公司控制 | 更新了募集资金总额，更新了各募投项 | | 第一节 本次发 | 权发生变化 | 目拟投入募集资金金额；更新了本次发 | | 行方案概要 | 六、本次发行方案已经取得有关 | 行导致控制权发生变化的内容；更新了 | | | 主管部门批准的情况以及尚需呈 | 本次发行已履行的相关程序 | | | 报批准的程序 | | | 第二节 董事会 | | | | 关于本次募集 | 一、本次募集资金使用计划 | 更新了募集资金总额，更新了各募投项 | | 资金使用的可 | 三、本次募集资金项目投资情况 | 目拟投入募集资 ...

浙江司太立制药股份有限公司 向特定对象发行 A 股股票募集资金使用 可行性分析报告（三次修订稿） 为提升公司的盈利能力，增强公司的核心竞争力，浙江司太立制药股份有限 公司（以下简称"公司"或"司太立"）拟向特定对象发行股票（以下简称"本 次发行"）募集资金。公司董事会对本次发行募集资金使用的可行性分析如下： 一、本次募集资金投资计划 公司本次发行股票募集资金总额（含发行费用）不超过148,000.00万元（含 本数），扣除发行费用后用于以下项目： 单位：万元 | 序号 | 项目 | | 项目投资总额 | 募集资金投资金额 | | --- | --- | --- | --- | --- | | 1 | 年产 1,550 吨非离子型 CT 造影剂系列原料药 | | 180,423.51 | 105,000.00 | | | 项目 | | | | | 2 | 年产 7,710 吨碘化合物及 CMO/CDMO | 产品项 | 56,266.08 | 15,000.00 | | | 目 | | | | | 3 | 补充流动资金 | | 28,000.00 | 28,000.00 | | | 合计 | | 264,689 ...

浙江司太立制药股份有限公司 第五届董事会第三次会议独立意见 浙江司太立制药股份有限公司 独立董事关于公司第五届董事会第三次会议相关事项的独立意见 浙江司太立制药股份有限公司（以下简称"公司"）第五届董事会第三次会议 于 2023 年 8 月 21 日召开，根据《公司章程》《关于在上市公司建立独立董事制度 的指导意见》等相关规定，我们作为公司独立董事，对会议资料进行了认真审阅， 基于自身的独立判断，现就公司第五届董事会第三次会议审议的相关事项发表如下 独立意见： 一、《关于向关联方转让股权的议案》 （以下无正文） 独立董事：胡吉明、毛美英、章晓科 2023 年 08 月 21 日 1 浙江司太立制药股份有限公司 第五届董事会第三次会议独立意见 [ 本页无正文，为公司第五届董事会第三次会议独立意见之签字页 ] 独立董事： 公司向关联方转让仙居县聚合金融服务有限公司 36%股权，转让符合公司战略 发展方向，不会对公司主营业务造成影响，不会导致公司合并报表范围发生变更。 本次交易价格合理，交易符合市场规则，公平、自愿，不会损害公司及股东，特别 是中小股东的利益。关联董事已回避表决，表决程序符合相关法律、法规和《公司 ...

证券代码：603520 证券简称：司太立 公告编号：2023-062 浙江司太立制药股份有限公司 关于向关联方转让股权的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）浙江司太立制药股份有限公司（以下简称"公司"）拟将持有的仙居 县聚合金融服务有限公司（统一社会信用代码：91331024MA28GHP78N，以下简 称"聚合金融"或"目标公司"）36%的股权全部转让给公司关联方胡锦生先生， 转让价格为人民币 1,980 万元。 （二）胡锦生担任公司董事，并持有公司股权，根据《上海证券交易所股 票上市规则》的相关规定，胡锦生为公司关联方，本次交易构成关联交易。 （三）本次交易不构成《上市公司重大资产重组管理办法》规定的重大资 产重组。至本次关联交易为止，公司不存在过去12个月内与同一关联人或与不 同关联人之间交易类别相关的关联交易达到3,000万元以上且占上市公司最近一 期经审计净资产绝对值5%以上的情形。本次交易无需提交股东大会审议。 一、关联交易概述 为提高经营管理效率，专注主营业务，公 ...

浙江司太立制药股份有限公司独立董事 关于向关联方转让股权事项的事前认可意见 根据《中华人民共和国公司法》、《关于在上市公司建立独立董事制度的指导意见》、《上海证券交 易所股票上市规则》、《浙江司太立股份有限公司章程》等有关规定，我们作为浙江司太立制药股份有限 公司（以下简称"公司"）的独立董事，我们对公司第五届董事会第三次会议拟审议的《关于向关联方转 让股权的议案》的有关材料进行了认真事前审查，基于独立判断，我们就拟审议的事项出具事前认可意见 如下： （一）《关于向关联方转让股权的议案》 公司向胡锦生转让仙居县聚合金融服务有限公司股权，有利于公司专注主营业务发展，提高管理效率， 符合公司战略发展方向，不存在损害公司及股东利益的情况。公司对本次关联交易所履行的审批、披露程 序符合有关规定。同意将该事项提交公司董事会审议。 独立董事：胡吉明、毛美英、章晓科 2023 年 8 月 17 日 [本页无正文，仅为浙江司太立制药股份有限公司独立董事关于向关联方转让股权事项的事前认可意见之签 字页] 胡吉明 毛美英 章晓科 ...

证券代码：603520 证券简称：司太立 公告编号：2023-063 浙江司太立制药股份有限公司 第五届监事会第三次会议决议公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）浙江司太立制药股份有限公司（以下简称"公司"）第五届监事会第 三次会议于 2023 年 8 月 21 日以现场结合通讯的方式召开，并以现场结合通讯的 方式进行表决。 （四）本次会议由监事会主席郑方卫先生召集并主持。 （五）本次会议召开符合《中华人民共和国公司法》及相关法律、法规、规 范性文件及《公司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过了《关于向关联方转让股权的议案》 同意公司将持有的仙居县聚合金融服务有限公司 36%的股权转让给公司关 联方胡锦生先生，转让价格为人民 1,980 万元。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 议案具体内容详见公司于 2023 年 8 月 22 日披露的《司太立关于向关联方转 让股权的公告》。 特此公告。 （二）公司已于 2023 年 8 月 1 ...

证券代码：603520 证券简称：司太立 公告编号：2023-036 浙江司太立制药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 05 月 17 日(星期三) 下午 13:00-14:30 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 05 月 10 日(星期三) 至 05 月 16 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stl@starrypharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 浙江司太立制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 565,907,679.16, representing a year-on-year increase of 9.40%[5] - Net profit attributable to shareholders decreased by 88.08% to CNY 9,567,951.36, while the net profit after deducting non-recurring gains and losses fell by 89.80% to CNY 7,456,100.10[5] - Basic and diluted earnings per share were both CNY 0.03, down 87.50% year-on-year[6] - Total operating revenue for Q1 2023 was ¥565,907,679.16, an increase of 9.3% compared to ¥517,298,394.90 in Q1 2022[19] - Net profit for Q1 2023 was ¥9,326,030.26, a decrease of 89.2% from ¥86,622,112.55 in Q1 2022[20] - Total comprehensive income for Q1 2023 was ¥9,563,899.40, a decrease from ¥83,710,512.02 in Q1 2022[21] Cash Flow - The net cash flow from operating activities was negative at CNY -42,083,050.09, an increase in outflow of 55.07% compared to the previous year[5] - Cash flow from operating activities for Q1 2023 was -¥42,083,050.09, an improvement from -¥93,672,558.25 in Q1 2022[21] - The net cash flow from investment activities was -$72,276,230.01, indicating a significant outflow compared to the previous period's -$69,200,922.32[22] - The net cash flow from financing activities was $210,517,413.67, slightly higher than the previous period's $199,520,943.36[22] - The company reported a net increase in cash and cash equivalents of $94,035,983.04, compared to $39,606,515.69 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,523,250,622.47, a 4.17% increase from the end of the previous year[6] - The company's current assets totaled RMB 2,352,090,790.54, up from RMB 2,171,638,504.78, indicating an increase of about 8.29%[14] - The company's total liabilities reached RMB 3,742,472,732.48, compared to RMB 3,530,966,127.81 at the end of 2022, marking an increase of around 5.99%[16] - The total equity attributable to shareholders rose to RMB 1,775,045,938.74 from RMB 1,765,240,118.24, showing a slight increase of about 0.56%[16] Expenses - The company reported a significant increase in sales expenses by 221.76%, primarily due to increased promotional costs[8] - Total operating costs for Q1 2023 were ¥555,018,778.78, up 25.5% from ¥442,145,752.91 in Q1 2022[19] - Research and development expenses increased to ¥34,844,731.55 in Q1 2023, up 24.5% from ¥27,968,697.96 in Q1 2022[19] - Sales expenses rose significantly to ¥18,954,376.69 in Q1 2023, compared to ¥5,890,758.13 in Q1 2022[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 34,672[9] Investment Activities - The company reported an investment loss of ¥1,275,335.52 in Q1 2023, compared to a gain of ¥12,315,000.57 in Q1 2022[20] - Cash received from investment income was $1,573,972.30, while cash received from the disposal of fixed assets was $6,000,000.00[22]

Financial Performance - The company's operating revenue for 2022 was CNY 2,131,239,988.65, representing a 6.57% increase compared to CNY 1,999,916,888.19 in 2021[22]. - The net profit attributable to shareholders of the listed company was a loss of CNY 75,845,700.75, a decrease of 123.43% from a profit of CNY 323,754,754.88 in 2021[22]. - The net cash flow from operating activities was a negative CNY 78,373,916.58, down 115.40% from CNY 508,839,385.25 in the previous year[22]. - Total assets increased by 8.31% to CNY 5,302,180,118.40 at the end of 2022, compared to CNY 4,895,377,815.83 at the end of 2021[22]. - The company's net assets attributable to shareholders decreased by 18.84% to CNY 1,765,240,118.24 from CNY 2,174,978,008.51 in 2021[22]. - The company reported a slight decrease of 0.30% in revenue after excluding non-main business income, totaling CNY 1,867,632,680.20[22]. - The basic earnings per share decreased by 123.40% to -0.22 RMB per share in 2022[24]. - The diluted earnings per share also fell by 123.16% to -0.22 RMB per share[24]. - The weighted average return on equity dropped by 19.85 percentage points to -3.81%[23]. - The net profit after deducting non-recurring gains and losses was -97.94 million RMB, down 131.81% year-on-year[33]. - The gross margin for the pharmaceutical manufacturing segment decreased by 12.88 percentage points to 25.27%[57]. Operational Challenges - The company faced challenges from a complex international environment, including inflation and supply chain disruptions[33]. - The company reported a significant decline in gross margin due to rising raw material prices and pricing constraints from centralized procurement[33]. - The company is focusing on the integration of intermediate, raw materials, and formulations to strengthen its supply chain resilience[35]. - The company is actively pursuing new technologies to lower production costs and improve product yield through ongoing technical improvements[34]. - The company faces operational risks related to raw material price fluctuations, particularly for iodine, which is subject to international market volatility[117]. - The company faces quality risks in raw materials, which could lead to product recalls and decreased demand for its APIs and intermediates[118]. - The transition to formulation sales is challenged by significant price drops due to national centralized procurement policies, impacting profitability for non-winning bidders[119]. - High investment and long cycles in drug R&D present risks, with uncertainties potentially leading to missed market opportunities and declining gross margins[120]. - Environmental and safety production risks are present, with potential penalties for non-compliance with national environmental regulations affecting operational performance[119]. Research and Development - The company invested CNY 134.62 million in R&D, accounting for 6.32% of its revenue[91]. - The company has 276 dedicated R&D personnel, with a PhD and Master's ratio of 13.41%[91]. - The company’s main products, including Iohexol injection and Gadobutrol injection, are currently under active research and registration[91]. - The company has established multiple R&D bases across various locations, including Zhejiang and Shanghai[91]. - The company has over 30 authorized invention patents and has established multiple research centers, enhancing its R&D capabilities in non-ionic contrast agents[49]. Market Strategy - The company aims to become the largest and most comprehensive manufacturer of contrast agent generics globally, focusing on filling domestic gaps in the market[46]. - The company plans to increase international market expansion efforts, targeting regions such as Europe, Southeast Asia, and South America[116]. - The company is transitioning towards digitalization, enhancing automation and intelligence in production processes to improve efficiency[115]. - The company will implement strategies to reduce raw material costs through deeper cooperation with suppliers and expanding procurement channels[114]. - The company is advancing its digital transformation initiatives to improve operational efficiency and reduce labor costs[34]. Corporate Governance - The company maintains a robust corporate governance structure, ensuring compliance with relevant laws and protecting shareholder rights[122]. - The company actively engages with investors through platforms and direct communication to ensure transparency and address inquiries[124]. - The company held one shareholders' meeting during the reporting period, adhering to legal and regulatory requirements[126]. - The company has established a comprehensive internal control system, with no significant deficiencies reported during the period[157]. - The company has committed to a share transfer limit of no more than 25% of total shares held during their tenure, with a six-month restriction post-resignation[183]. Environmental Compliance - The company achieved a total wastewater discharge of 494,697 tons in 2022, with a COD discharge of 139.985 tons[160]. - The company maintained compliance with environmental discharge standards, with no exceedances reported for key pollutants[162]. - The company has established a hazardous waste storage facility with a maximum capacity of 650 tons, complying with environmental protection standards[166]. - The company has implemented a comprehensive environmental risk emergency mechanism, ensuring effective response to environmental incidents[168]. - The company’s wastewater monitoring includes key pollutants such as COD, pH, and ammonia nitrogen, with automatic online monitoring every 2 hours for certain indicators[169]. Shareholder Information - The company plans to distribute a cash dividend of CNY 2 per 10 shares to all shareholders, pending approval at the 2022 annual general meeting[5]. - The total number of shares held by Hu Jingsheng increased from 50,274,000 at the beginning of the year to 70,383,600 at the end of the year, reflecting an increase of 20,109,600 shares due to a capital reserve distribution of 4 shares for every 10 shares held[128]. - The total number of shares held by Hu Jian increased from 44,100,000 to 61,740,000, with an increase of 17,640,000 shares attributed to the same capital reserve distribution[128]. - The total number of shares held by Shen Weiyi increased from 41,800 to 58,520, resulting in an increase of 16,720 shares due to the capital reserve distribution[128]. - The total compensation for Hu Jingsheng was 126.34 million yuan, while Hu Jian received 97.50 million yuan in compensation[128]. Financial Management - The company has engaged in cash asset management with a total amount of 13,000,000 RMB from idle raised funds[199]. - The company has multiple financial management agreements with banks, with amounts of 3,000,000 RMB and varying annualized returns between 3.00% and 3.20%[200]. - The company has a financial management agreement with China Construction Bank for 3,000,000 RMB with an expected return of 3.20%[200]. - The company has a financial management agreement with Bank of China for 3,000,000 RMB with an expected return of 3.20%[200]. - The company has a financial management agreement with Shanghai Pudong Development Bank for 3,000,000 RMB with an expected return of 3.10%[200].